The pharmaceutical industry is poised for a paradigm shift: moving away from animal models prior to human trials. This conference unites leaders from pharma, academia, and the exhibitor ecosystem to address the critical question: What is needed to engineer the post-animal drug discovery pipeline? Achieving this future requires fundamental changes – testing compounds earlier in more relevant cells, at significantly larger scales, to generate the comprehensive foundational data necessary to reduce animal dependency.

This event is essential for professionals across the cell-based discovery continuum who are actively preparing for an AI-driven future. Through collaborative dialogue, they aim to help this community rework early discovery from animal-gated milestones to human-first decision making. This new blueprint needs us to deliberate on how our hit-to-lead processes should change, where cells should replace animals, and how AI can enhance the predictive accuracy of our efforts to deliver transformative therapies.

View the event here.